-
The FDA has approved the first of a new class of agents, the vaptans. Conivaptan, the first arginine vasopressin receptor antagonist, is approved for the management of serious sodium/water imbalance. It will be marketed by Astellas Pharma US, Inc as Vaprisol®.
-
This case series and prospective observational study describe propylene glycol toxicity in patients receiving IV benzodiazepines. The authors estimate the incidence of this important but unrecognized complication to be 19%.
-
Illnesses produced by vascular diseases are far and away the most common cause of death in the developed world and, amazingly enough, will become the leading cause of death even in the developing world by 2020.1 Identifying individuals at increased risk of coronary artery heart disease (CHD) is critical in preventing CHD and, in 2002, the Adult Treatment Panel III (ATP III)2 reaffirmed its previous position by concluding that low-density lipoprotein cholesterol (LDL-C) would remain the cornerstone of lipid management.
-
The use of a steroid ointment following a 20-minute soak may relieve chronic skin conditions.
-
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout; Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients with Unstable Coronary Artery Disease; Dietary Fiber Intake and Risk of Colorectal Cancer
-
Acid suppression, particularly with proton pump inhibitors (PPIs) is correlated with an increased risk of community-acquired Clostridium difficile colitis.
-
Metabolic syndrome is common and is associated with an increased risk for CVD and T2DM in both sexes.
-
Tretinoin solution helps heal diabetic foot ulcers.
-
The FDA has approved a cfc-free levalbuterol aerosol inhaler for the treatment of asthma. Levalbuterol is the active isomer of albuterol and has been available in a nebulized solution for many years. This new formulation is marketed by Sepracor as Xopenex HFA.
-
A 6-year retrospective study shows that 45% of Medicare patients with state-funded drug benefits who initiate a medication for osteoporosis do not continue to take it as prescribed one year later and 52% are no longer compliant 5-years later.